A detailed history of Vanguard Group Inc transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,770,525 shares of SPRO stock, worth $2.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,770,525
Previous 1,653,432 7.08%
Holding current value
$2.18 Million
Previous $2.84 Million 19.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.27 - $1.8 $148,708 - $210,767
117,093 Added 7.08%
1,770,525 $2.3 Million
Q1 2024

May 10, 2024

BUY
$1.35 - $1.79 $13,061 - $17,318
9,675 Added 0.59%
1,653,432 $2.84 Million
Q4 2023

Feb 14, 2024

BUY
$1.0 - $1.47 $86,161 - $126,656
86,161 Added 5.53%
1,643,757 $2.42 Million
Q3 2023

Nov 14, 2023

BUY
$1.2 - $1.63 $37,346 - $50,728
31,122 Added 2.04%
1,557,596 $1.88 Million
Q2 2023

Aug 14, 2023

BUY
$1.42 - $1.95 $141,862 - $194,810
99,903 Added 7.0%
1,526,474 $2.21 Million
Q1 2023

May 15, 2023

BUY
$1.35 - $2.0 $502,447 - $744,366
372,183 Added 35.3%
1,426,571 $2.07 Million
Q4 2022

Feb 10, 2023

BUY
$1.55 - $2.12 $1,030 - $1,409
665 Added 0.06%
1,054,388 $1.82 Million
Q3 2022

Nov 14, 2022

SELL
$0.68 - $2.2 $130,742 - $422,991
-192,269 Reduced 15.43%
1,053,723 $2.11 Million
Q2 2022

Aug 12, 2022

SELL
$0.74 - $7.44 $94,672 - $951,843
-127,936 Reduced 9.31%
1,245,992 $924,000
Q1 2022

May 13, 2022

BUY
$7.87 - $15.15 $177,468 - $341,632
22,550 Added 1.67%
1,373,928 $12 Million
Q4 2021

Feb 14, 2022

BUY
$13.09 - $18.77 $770,739 - $1.11 Million
58,880 Added 4.56%
1,351,378 $21.6 Million
Q3 2021

Nov 12, 2021

BUY
$13.03 - $19.51 $204,675 - $306,463
15,708 Added 1.23%
1,292,498 $23.8 Million
Q2 2021

Aug 13, 2021

BUY
$12.22 - $15.79 $15.6 Million - $20.2 Million
1,276,790 New
1,276,790 $17.8 Million

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $43.1M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.